These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16765555)

  • 1. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
    Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):351-6. PubMed ID: 16765555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):283-7. PubMed ID: 15313534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.
    Sader HS; Biedenbach DJ; Streit JM; Jones RN
    Int J Antimicrob Agents; 2005 Jan; 25(1):89-92. PubMed ID: 15620832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
    Jones RN; Mendes RE; Sader HS
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv17-31. PubMed ID: 21115451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2013 Apr; 41(4):337-42. PubMed ID: 23466338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefdinir: an oral alternative to parenteral cephems.
    Chatterjee A; Moland ES; Thomson KS
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):259-64. PubMed ID: 15808317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
    Giordano PA; Elston D; Akinlade BK; Weber K; Notario GF; Busman TA; Cifaldi M; Nilius AM
    Curr Med Res Opin; 2006 Dec; 22(12):2419-28. PubMed ID: 17257456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections.
    Bonsu BK; Shuler L; Sawicki L; Dorst P; Cohen DM
    Acad Emerg Med; 2006 Jan; 13(1):76-81. PubMed ID: 16365328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir.
    Payne DJ; Amyes SG
    Drugs Exp Clin Res; 1992; 18(6):225-31. PubMed ID: 1478161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
    París MM; Devcich KJ
    Cutis; 2004 May; 73(5 Suppl):14-8. PubMed ID: 15182160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on treating uncomplicated skin and skin structure infections.
    Rosen T
    J Drugs Dermatol; 2005; 4(6 Suppl):s9-14. PubMed ID: 16300224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
    Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.